<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00124514</url>
  </required_header>
  <id_info>
    <org_study_id>2008-1045</org_study_id>
    <secondary_id>FD-R-00239</secondary_id>
    <nct_id>NCT00124514</nct_id>
    <nct_alias>NCT00088244</nct_alias>
  </id_info>
  <brief_title>Triptorelin for Ovary Protection in Childhood Onset Lupus</brief_title>
  <official_title>Triptorelin for Ovary Protection in Childhood Onset Lupus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Watson Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of triptorelin when used for the protection&#xD;
      of the ovaries (pair of female reproductive organs) during cyclophosphamide therapy for&#xD;
      systemic lupus erythematosus (SLE; lupus) and to see what effects (good or bad) it has on&#xD;
      patients. The study will be done with female patients who have been diagnosed with systemic&#xD;
      lupus erythematosus, are younger than 21 years of age, and require intravenous&#xD;
      cyclophosphamide to control the disease. Each patient will be in the study for approximately&#xD;
      23 months, until 4 months after the intravenous cyclophosphamide treatment has been&#xD;
      completed.&#xD;
&#xD;
      This study is currently being conducted at 3 sites across the United States and Brazil (Los&#xD;
      Angeles, Cincinnati and San Paulo Brazil). A total of 50 patients will participate in this&#xD;
      study.&#xD;
&#xD;
      Each patient will be randomized (assigned) to one of 5 groups. Randomization means that&#xD;
      patients are put into a group completely by chance. It is like flipping a coin. Neither the&#xD;
      patient nor the study staff knows what group the patient is in. The patient has a 20% chance&#xD;
      of being placed in any group.&#xD;
&#xD;
      This is a dose escalation study, each patient will receive the first dose of the study drug&#xD;
      (T1 - T4, placebo). If a patient has complete ovarian suppression on day 27 after the initial&#xD;
      injection of study drug, then she will remain on this weight-adjusted dose of study drug&#xD;
      throughout the study. The dose will be increased up for a weight gain of 5kg or greater. The&#xD;
      dose will not be adjusted downward for a weight loss. If COS was not maintained with the 1st&#xD;
      dose of study drug, then the subsequently injected 2nd dose will be increased by 25% or at&#xD;
      least 20 microgram/kg/dose. The maximal dose of 150 microgram/kg/dose will not be exceeded.&#xD;
      The absolute maximum dose is 20 mg.&#xD;
&#xD;
      Funding Source: FDA OOPD and Watson Pharmaceuticals&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lupus is an autoimmune disease that may harm all organs in the body and especially affects&#xD;
      the kidney, brain, skin and lungs. Cyclophosphamide is a very effective medication to treat&#xD;
      lupus, but it can damage the ovaries (pair of reproductive organs).&#xD;
&#xD;
      Only female lupus patients may participate in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose of Triptorelin for Ovarian Suppression</measure>
    <time_frame>baseline to week 24</time_frame>
    <description>Dose escalation was initiated If COS was not maintained with the 1st dose of study drug. Subsequent doses were increased by 25% or at least 20μg/kg dose. This procedure of dose increases by 25% or at least 20μg/kg dose was repeated until COS was maintained. Absolute max dose 7.8mg. Triptorelin (T1-T4) groups were pooled for analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Time of Triptorelin Treatment to Achieve Ovarian Suppression</measure>
    <time_frame>baseline to week 24</time_frame>
    <description>Time to ovarian suppression, based on suppressed LH levels, after the initial dose of triptorelin. Due to the dose escalation during the study, Triptorelin (T1-T4) groups were pooled for analysis.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Triptorelin T1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triptorelin Pamoate 25 μg/kg body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triptorelin T2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triptorelin Pamoate 50 μg/kg body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triptorelin T3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triptorelin Pamoate 75 μg/kg body weight T3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triptorelin T4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triptorelin Pamoate 100 μg/kg body weight T4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin pamoate</intervention_name>
    <description>IM injection given monthly</description>
    <arm_group_label>Triptorelin T1</arm_group_label>
    <other_name>Trelstar Depot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin Pamoate</intervention_name>
    <description>IM injection given monthly</description>
    <arm_group_label>Triptorelin T2</arm_group_label>
    <other_name>Trelstar Depot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin Pamoate</intervention_name>
    <description>IM injection given monthly</description>
    <arm_group_label>Triptorelin T3</arm_group_label>
    <other_name>Trelstar Depot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin Pamoate</intervention_name>
    <description>IM injection given monthly</description>
    <arm_group_label>Triptorelin T4</arm_group_label>
    <other_name>Trelstar Depot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo 0.9% normal saline IM injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo 0.9% normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females under the age of 21 and non-pregnant&#xD;
&#xD;
          -  Tanner stage of 2 or above as determined by physical examination of breast stage&#xD;
&#xD;
          -  Diagnosis with SLE using the updated American College of Rheumatology (ACR)&#xD;
             Classification Criteria for SLE 1&#xD;
&#xD;
          -  Severe SLE requiring cyclophosphamide therapy&#xD;
&#xD;
          -  Bone mineral density z-score &gt; - 2.0&#xD;
&#xD;
          -  Must be using a medically acceptable form of birth control during the study and must&#xD;
             not be pregnant at the screening visit&#xD;
&#xD;
          -  No clinically significant abnormal findings other than those consistent with the&#xD;
             diagnosis of childhood-onset SLE (cSLE) on the physical examination, medical history&#xD;
             or clinical laboratory results during screening&#xD;
&#xD;
          -  Currently on any combination of medication but must not have been treated with more&#xD;
             than one dose of cyclophosphamide or other gonadotoxic medications in the past&#xD;
&#xD;
          -  Voluntary consent or, if under the age of consent, assent to participate in this study&#xD;
             with permission by a legal guardian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male patients of any age&#xD;
&#xD;
          -  Female patients with a Tanner stage of 1&#xD;
&#xD;
          -  Positive blood pregnancy test at screening or taking oral or injectable birth-control&#xD;
             medications&#xD;
&#xD;
          -  Prior exposure to more than one dose of gonadotoxic medications including&#xD;
             cyclophosphamide&#xD;
&#xD;
          -  History of allergic or adverse response to triptorelin&#xD;
&#xD;
          -  Diagnosed with hypogonadism prior to cyclophosphamide exposure&#xD;
&#xD;
          -  Acutely life-threatening disease activity that prohibits inclusion in a clinical trial&#xD;
&#xD;
          -  History of clinically significant gastrointestinal tract, renal, hepatic, endocrine,&#xD;
             oncologic, pulmonary (asthma accepted), or cardiovascular disease; or a history of&#xD;
             tuberculosis, epilepsy, diabetes, depression, psychosis, or any other non-cSLE&#xD;
             condition, which in the opinion of the physician, would jeopardize the safety of the&#xD;
             subject or impact the validity of the study results&#xD;
&#xD;
          -  Patient age 18 years of younger with severe depression as defined by a CDI (Children's&#xD;
             Depression Inventory) score of &gt; 23 or a patient age 19 to 21 years with severe&#xD;
             depression as defined by a BDI (Beck's Depression Inventory) score &gt; 29&#xD;
&#xD;
          -  Patient admits to suicidal thoughts at screening visit&#xD;
&#xD;
          -  Bone mineral density lower than z = -2.0.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hermine I Brunner, M.D. M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morgan Stanley Children's Hospital of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Sao Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 26, 2005</study_first_submitted>
  <study_first_submitted_qc>July 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2005</study_first_posted>
  <results_first_submitted>September 9, 2020</results_first_submitted>
  <results_first_submitted_qc>December 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 5, 2021</results_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Medical Center, Cincinnati</investigator_affiliation>
    <investigator_full_name>Hermine Brunner, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>SLE</keyword>
  <keyword>Lupus</keyword>
  <keyword>Ovarian damage</keyword>
  <keyword>Menopause</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>130 patients were screened for the study and 31 were randomized to one of 5 arms to start. The arms determined the starting dose of Triptorelin. All arms participated in dose escalation until the subjects reached and maintained COS.&#xD;
2 subjects withdrew prior to start of study procedures.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Normal Saline</description>
        </group>
        <group group_id="P2">
          <title>Triptorelin T1</title>
          <description>Triptorelin Pamoate 25 μg/kg body weight starting dose&#xD;
Dose escalation initiated if COS was not maintained with the 1st dose of study drug. The subsequently injected 2nd dose was increased by 25% or at least 20 μg/kg dose. This procedure of dose increases repeated until COS was maintained.</description>
        </group>
        <group group_id="P3">
          <title>Triptorelin T2</title>
          <description>Triptorelin Pamoate 50 μg/kg body weight starting dose&#xD;
Dose escalation initiated if COS was not maintained with the 1st dose of study drug. The subsequently injected 2nd dose was increased by 25% or at least 20 μg/kg dose. This procedure of dose increases repeated until COS was maintained.</description>
        </group>
        <group group_id="P4">
          <title>Triptorelin T3</title>
          <description>Triptorelin Pamoate 75 μg/kg body weight starting dose&#xD;
Dose escalation initiated if COS was not maintained with the 1st dose of study drug. The subsequently injected 2nd dose was increased by 25% or at least 20 μg/kg dose. This procedure of dose increases repeated until COS was maintained.</description>
        </group>
        <group group_id="P5">
          <title>Triptorelin T4</title>
          <description>Triptorelin Pamoate 100 μg/kg body weight starting dose&#xD;
Dose escalation initiated if COS was not maintained with the 1st dose of study drug. The subsequently injected 2nd dose was increased by 25% or at least 20 μg/kg dose. This procedure of dose increases repeated until COS was maintained.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Normal Saline&#xD;
placebo: placebo 0.9% normal saline IM injection</description>
        </group>
        <group group_id="B2">
          <title>Triptorelin T1</title>
          <description>Triptorelin Pamoate 25 μg/kg body weight</description>
        </group>
        <group group_id="B3">
          <title>Triptorelin T2</title>
          <description>Triptorelin Pamoate 50 μg/kg body weight</description>
        </group>
        <group group_id="B4">
          <title>Triptorelin T3</title>
          <description>Triptorelin Pamoate 75 μg/kg body weight</description>
        </group>
        <group group_id="B5">
          <title>Triptorelin T4</title>
          <description>Triptorelin Pamoate 100 μg/kg body weight</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="2"/>
            <count group_id="B6" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.9" spread="2.1"/>
                    <measurement group_id="B2" value="15.9" spread="2.6"/>
                    <measurement group_id="B3" value="16.5" spread="2.2"/>
                    <measurement group_id="B4" value="13.0" spread="2.1"/>
                    <measurement group_id="B5" value="12.50" spread="0"/>
                    <measurement group_id="B6" value="15.4" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dose of Triptorelin for Ovarian Suppression</title>
        <description>Dose escalation was initiated If COS was not maintained with the 1st dose of study drug. Subsequent doses were increased by 25% or at least 20μg/kg dose. This procedure of dose increases by 25% or at least 20μg/kg dose was repeated until COS was maintained. Absolute max dose 7.8mg. Triptorelin (T1-T4) groups were pooled for analysis.</description>
        <time_frame>baseline to week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Normal Saline&#xD;
placebo: placebo 0.9% normal saline IM injection</description>
          </group>
          <group group_id="O2">
            <title>Triptorelin (T1-T4)</title>
            <description>Due to the dose escalation during the study, Triptorelin (T1-T4) groups were pooled for analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose of Triptorelin for Ovarian Suppression</title>
          <description>Dose escalation was initiated If COS was not maintained with the 1st dose of study drug. Subsequent doses were increased by 25% or at least 20μg/kg dose. This procedure of dose increases by 25% or at least 20μg/kg dose was repeated until COS was maintained. Absolute max dose 7.8mg. Triptorelin (T1-T4) groups were pooled for analysis.</description>
          <units>μg/kg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Ovarian suppression not reached in placebo group</measurement>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Time of Triptorelin Treatment to Achieve Ovarian Suppression</title>
        <description>Time to ovarian suppression, based on suppressed LH levels, after the initial dose of triptorelin. Due to the dose escalation during the study, Triptorelin (T1-T4) groups were pooled for analysis.</description>
        <time_frame>baseline to week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Normal Saline&#xD;
placebo: placebo 0.9% normal saline IM injection</description>
          </group>
          <group group_id="O2">
            <title>Triptorelin</title>
            <description>Triptorelin Pamoate&#xD;
Due to the dose escalation during the study, Triptorelin (T1-T4) groups were pooled for analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Time of Triptorelin Treatment to Achieve Ovarian Suppression</title>
          <description>Time to ovarian suppression, based on suppressed LH levels, after the initial dose of triptorelin. Due to the dose escalation during the study, Triptorelin (T1-T4) groups were pooled for analysis.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Ovarian suppression not reached in placebo group</measurement>
                    <measurement group_id="O2" value="18" lower_limit="15" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Due to the dose escalation during the study, Triptorelin (T1-T4) groups were pooled for analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Group</title>
          <description>Normal Saline&#xD;
placebo: placebo 0.9% normal saline IM injection</description>
        </group>
        <group group_id="E2">
          <title>Triptorelin</title>
          <description>Triptorelin Pamoate&#xD;
Due to the dose escalation during the study, Triptorelin (T1-T4) groups were pooled for analysis.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropsychiatric lupus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cutaneous vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Diffuse vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hermine Brunner</name_or_title>
      <organization>cincinnatichildrens</organization>
      <phone>5136367982</phone>
      <email>hermine.brunner@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

